Phase II data show 5HT1D agonist MAP0004 is effective in Migraine

Phase II data published in the July issue of Current Medical Research and Opinion show MAP Pharmaceutical’s 5HT1D agonist MAP0004, an orally inhaled and self-administered therapy, to demonstrate efficace in migraine.

MAP Pharmas 5-HT1D agonist enter Phase III for migraine

MAP Pharmaceuticals has initiated its first Phase 3 trial of MAP0004 its 5-HT1D agonist for the treatment of Migraine

NuPathe report Phase I results with transdermal sumatriptan product NP101

Phase I Data Presented at the American Headache Society meeting show NuPathe’s transdermal sumatriptan product NP101 to demonstrate efficacy in the treatment of migraine. The drug was well tolerated and adverse events for NP101 were generally mild

MAPS dihydroergotamine MAP0004 demonstrates preclincal activity

Data presented at the American Headache Society meeting shows that MAP Pharmaceutical’s inhaled dihydroergotamine MAP0004 stimulated receptors known to relieve migraine without activating receptors associated with side effects

Theravance describe synthesis of 5-HT1D ligands by dimerization of 5-HT1 ligands

Theravance describe a series of 5-HT1D ligands derived by dimerization of 5-HT1 ligands including LY-334370, a selective agonist of 5-HT1F receptor

Pozen transfer IND/NDA for Treximet to GSK

Pozen have transferred the IND and NDA for Treximet (Sumatriptan/Naproxen) following its successful approval in April for the acute treatment of migraine attacks, with or without aura.